By Justin Petrone

iGenix, a Seattle-based contract research and laboratory services company, has launched its first diagnostic assay, which runs on Illumina's BeadXpress system.

The pharmacogenomic assay, which genotypes two genes in order to guide dosing of the anticoagulant warfarin, was built as a "proof-of-principle test" as part of the firm's effort to meet Washington State clinical laboratory regulations and is "one of several" in iGenix's pipeline, according to a company official.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.